GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Click Here For Complete Report at:
http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes:
• Disease overview, as well as treatment algorithms and treatment usage patterns
• Market size and forecast for the APAC breast cancer market from 2013 to 2020- Major marketed products in the APAC region along with a heat map of product performance
Click Here and Read Other Reports of This Category:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Reasons to buy
The report will enhance your decision-making capability by allowing you to:
• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Read this report at LinkedIn:
https://www.linkedin.com/pulse/breast-cancer-therapeutics-markets-research-2020-radiant
Related reports by Radiant Insights:
Lupus Nephritis - Pipeline Review, H1 2015:
http://www.radiantinsights.com/research/lupus-nephritis-pipeline-review-h1-2015
Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H1 2015', provides an overview of the Lupus Nephritis's therapeutic pipeline.
Osteosarcoma - Pipeline Review, H1 2015:
http://www.radiantinsights.com/research/osteosarcoma-pipeline-review-h1-2015
Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H1 2015', provides an overview of the Osteosarcoma's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media ContactCompany Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist - USA
Email:Send Email
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options
